Capricor Therapeutics, Inc. (CAPR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Capricor Therapeutics, Inc. (CAPR) Healthcare & Pipeline Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in cell and exosome-based therapies, with its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy and COVID-19-related cytokine storms. The company focuses on innovative treatments for diseases with unmet medical needs within the biotechnology sector.

What Is the Investment Thesis for CAPR?

Capricor Therapeutics presents a notable research candidate due to its focus on innovative cell and exosome-based therapies. The successful completion of the Phase III clinical trial for CAP-1002 in treating late-stage Duchenne muscular dystrophy (DMD) is a significant milestone. Further clinical trials, specifically the Phase II trial for cytokine storms associated with SARS-CoV-2, could provide additional value. The development of CAP-2003 for trauma-related injuries and COVID-19 vaccine candidates offers potential long-term growth avenues. However, the company's reliance on clinical trial outcomes and regulatory approvals poses inherent risks. With a market capitalization of $1.60 billion and a beta of 0.48, Capricor exhibits moderate volatility. Key value drivers include successful clinical trial results, strategic partnerships, and regulatory approvals. Upcoming data releases from ongoing clinical trials will be crucial for investor sentiment.

Based on FMP financials and quantitative analysis

CAPR Key Highlights

CAP-1002 has completed Phase III clinical trial for Duchenne muscular dystrophy (DMD), demonstrating potential in a critical unmet need.

• CAP-1002 is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2, addressing complications from COVID-19.
• CAP-2003 is in pre-clinical development for trauma related injuries, indicating pipeline expansion beyond DMD and COVID-19.
• Collaboration with Lonza Houston, Inc. ensures reliable clinical manufacturing of CAP-1002.
• Market capitalization of $1.60 billion reflects investor valuation of Capricor's pipeline and technology.

Who Are CAPR's Competitors?

CAPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CAPR's Key Strengths?

Lead candidate CAP-1002 with positive Phase III trial results for DMD.

• Innovative cell and exosome-based therapeutic platforms.
• Collaboration with Lonza for manufacturing.
• Pipeline of product candidates targeting multiple indications.

What Are CAPR's Weaknesses?

Reliance on clinical trial outcomes and regulatory approvals.

• Limited commercialization experience.
• High research and development costs.
• Potential competition from larger pharmaceutical companies.

What Could Drive CAPR Stock Higher?

Data readout from Phase II clinical trial of CAP-1002 for COVID-19 cytokine storm.

• Initiation of clinical trials for CAP-2003 in trauma-related injuries.
• Regulatory discussions with the FDA regarding CAP-1002 approval pathway for DMD.
• Progress in the development of COVID-19 vaccine candidates.

What Are the Key Risks for CAPR?

Financial-distress signal — its Altman Z-Score of 0.54 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-59.3%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Failure to obtain regulatory approvals for CAP-1002 or other product candidates.
• Unfavorable clinical trial results that could delay or halt development.
• Competition from other companies developing therapies for DMD, COVID-19, and other indications.
• Dependence on securing additional funding to support research and development activities.

What Are the Growth Opportunities for CAPR?

• Expansion of CAP-1002 into new DMD patient segments: While CAP-1002 has completed Phase III trials for late-stage DMD, expanding its application to earlier stages of the disease represents a significant growth opportunity. The DMD market is estimated to reach $4 billion by 2028, and capturing a larger share of this market through expanded indications could drive substantial revenue growth. This expansion depends on further clinical trials demonstrating efficacy and safety in broader patient populations, with potential timelines extending over the next 3-5 years.
• Development and commercialization of CAP-2003 for trauma-related injuries: CAP-2003, currently in pre-clinical development, targets trauma-related injuries and conditions. The market for trauma care is substantial, driven by increasing incidence of accidents and injuries. Successful development and commercialization of CAP-2003 could provide a new revenue stream for Capricor. Pre-clinical studies are expected to continue over the next 1-2 years, followed by clinical trials, potentially leading to commercialization within 5-7 years.
• Advancement of COVID-19 vaccine candidates: Capricor is developing two vaccine candidates for the potential prevention of COVID-19. While the COVID-19 vaccine market has become competitive, there remains a need for improved vaccines that offer broader protection and longer-lasting immunity. Successful development and approval of Capricor's vaccine candidates could generate significant revenue, particularly if they demonstrate superior efficacy or address emerging variants. Clinical trials are expected to progress over the next 2-3 years, with potential for market entry within 3-5 years.
• Strategic partnerships and collaborations: Capricor's collaboration with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002 highlights the importance of strategic partnerships. Forming additional collaborations with pharmaceutical companies, research institutions, or other biotechnology firms could accelerate the development and commercialization of its pipeline candidates. These partnerships could provide access to funding, expertise, and distribution networks, enhancing Capricor's growth prospects. The timeline for forming new partnerships is ongoing and opportunistic.
• Expansion into new therapeutic areas: Capricor's expertise in cell and exosome-based therapeutics could be leveraged to expand into new therapeutic areas beyond DMD, COVID-19, and trauma-related injuries. Exploring opportunities in other areas with unmet medical needs, such as cardiovascular diseases, neurological disorders, or autoimmune conditions, could diversify Capricor's pipeline and reduce its reliance on specific indications. This expansion would require significant investment in research and development, with potential timelines extending over the next 5-10 years.

What Are CAPR's Competitive Advantages?

• Proprietary cell and exosome-based therapeutic platforms.
• Clinical trial data supporting the efficacy of CAP-1002.
• Strong intellectual property portfolio protecting its technologies.
• Established manufacturing capabilities through collaboration with Lonza.

What Does CAPR Do?

Capricor Therapeutics, Inc., founded in 2005 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to the development of transformative cell and exosome-based therapeutics. The company aims to address a spectrum of diseases and disorders through innovative approaches. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 has completed a Phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. Additionally, CAP-1002 is in a Phase II clinical trial for treating cytokine storms associated with SARS-CoV-2, the virus responsible for COVID-19. Beyond CAP-1002, Capricor is developing CAP-2003, currently in pre-clinical development, targeting trauma-related injuries and conditions. The company is also working on two vaccine candidates in the development stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, ensuring a reliable supply of its cell therapy candidate for DMD and other potential indications.

What Products and Services Does CAPR Offer?

• Develop cell-based therapeutics for treating diseases.
• Focus on exosome-based therapies for various disorders.
• Advance CAP-1002 for Duchenne muscular dystrophy (DMD) treatment.
• Investigate CAP-1002 for cytokine storms associated with SARS-CoV-2.
• Develop CAP-2003 for trauma-related injuries.
• Create vaccine candidates for COVID-19 prevention.
• Collaborate with Lonza Houston for clinical manufacturing.

How Does CAPR Make Money?

• Develop and commercialize cell and exosome-based therapeutics.
• Generate revenue through sales of approved therapies.
• Out-license technologies and therapies to other companies.
• Secure funding through grants, partnerships, and equity financing.

What Industry Does CAPR Operate In?

Capricor Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for cell and gene therapies is experiencing rapid growth, driven by advancements in technology and increasing demand for personalized medicine. Capricor's focus on cell and exosome-based therapeutics positions it within this evolving landscape. Key competitors include companies developing similar therapies for DMD, COVID-19, and other indications. The biotechnology industry is subject to stringent regulatory requirements, with the FDA playing a critical role in approving new therapies. The industry is also influenced by trends such as precision medicine, gene editing, and the increasing use of artificial intelligence in drug discovery.

Who Are CAPR's Key Customers?

• Patients suffering from Duchenne muscular dystrophy (DMD).
• Patients experiencing cytokine storms associated with SARS-CoV-2.
• Individuals at risk of contracting COVID-19.
• Hospitals and medical centers administering Capricor's therapies.

Company Profile

Capricor Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Linda Marbán. CAPR has traded publicly since 2007.

How Capricor Therapeutics, Inc. Is Valued

Analyst price targets span from $3.50 to $25.00, with a consensus of $10.63. At the current price of $8.30, that implies approximately 28% upside potential. Relative to its peer group, CAPR's quantitative score of 38/100 is below the peer average of 88/100.

Return on equity for Capricor Therapeutics, Inc. stands at -59.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.7%, the inverse of the P/E and a quick read on earnings relative to price.

Capricor Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.54 places it in the distress zone, a signal of elevated financial risk.

Capricor Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 10.5% below estimates on average.

Wall Street analysts project Capricor Therapeutics, Inc. revenue of about $92.2M for fiscal 2026, with EPS near $-1.54. The estimate reflects 6 contributing analysts.

Over the past six months, Capricor Therapeutics, Inc. insiders filed 29 SEC Form 4 transactions — 17 sales and 12 purchases. On net that is roughly 19K shares disposed (about $725K), a signal worth weighing alongside the fundamentals.

CAPR Financials

CAPR Latest News

CAPR Analyst Consensus

CAPR MoonshotScore

CAPR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources